Thus, in vivo experiments using immune-deficient and immune-competent mice are warranted to evaluate the therapeutic potential of OBP-301 and OBP-702 against KRAS/BRAF-mutant CRC tumors in monotherapy and combination therapy with small molecules targeting the MEK-ERK pathway. Here, MAP2K7 is linked to colorectal carcinoma.